Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
22 June, 2024 12:57 IST
Cipla gets final nod for Lanreotide Injection
Source: IRIS | 20 Dec, 2021, 04.51PM
Rating: NAN / 5 stars.
Comments  |  Post Comment

Cipla, a leading drug maker, announced that the company has received final approval for its Lanreotide Injection, from the United States Food and Drug Administration (US FDA). The FDA approval was based on a New Drug Application (NDA) submitted under the 505(b)(2) filing pathway.

Lanreotide Injection is supplied in 60 mg/0.2 mL, 90 mg/0.3 mL, and 120 mg/0.5 mL singledose pre-filled syringes. It is indicated for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs).

Umang Vohra (MD and Global CEO, Cipla) said, "We are pleased to receive the final approval for Lanreotide injection from the USFDA. Enabling access to high-quality treatments is core to our purpose of "Caring for Life". This approval is a significant step for our US business and is in line with our aspiration to continue growth in our complex product pipeline and address unmet patient needs.

The active ingredient, route of administration and strengths are the same as SOMATULINE DEPOT, from Ipsen Biopharmaceuticals Inc.

According to IQVIA, SOMATULINE DEPOT had US sales of approximately USD 867 million for the 12-month period ending October 2021.

Shares of the company gained Rs 34.75, or 4.04%, to trade at Rs 894.60. The total volume of shares traded was 190,460 at the BSE (3.17 p.m, Monday).

 Post Comment
Name Email
Security Code type    into this box
Related Articles
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer